The intricate metabolism of pancreatic cancers

Felipe Camelo, Quy Hoa Le Thi

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Oncogenic KRAS regulates glucose and glutamine metabolism in pancreatic cancer cells.MUC1 overexpression leads to increased glucose metabolism.p53 functions predict the sensitivity of pancreatic cancer tumors to glycolytic inhibition.Targeting alpha-ketoglutarate dehydrogenase function by CPI-613 to slow mitochondrial metabolism.The antidiabetic drug, metformin, targets pancreatic cancer stem cells.Combined therapy is used to target pancreatic metabolism heterogeneity.

Original languageEnglish (US)
Title of host publicationAdvances in Experimental Medicine and Biology
PublisherSpringer New York LLC
Pages73-81
Number of pages9
DOIs
StatePublished - Jan 1 2018

Publication series

NameAdvances in Experimental Medicine and Biology
Volume1063
ISSN (Print)0065-2598
ISSN (Electronic)2214-8019

Keywords

  • Combined therapy
  • Glucose metabolism
  • Glutamine metabolism
  • KRAS mutation
  • Pancreatic ductal adenocarcinoma

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'The intricate metabolism of pancreatic cancers'. Together they form a unique fingerprint.

Cite this